Jens Pahl

1.3k total citations
20 papers, 794 citations indexed

About

Jens Pahl is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jens Pahl has authored 20 papers receiving a total of 794 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 11 papers in Oncology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jens Pahl's work include Immune Cell Function and Interaction (17 papers), CAR-T cell therapy research (11 papers) and T-cell and B-cell Immunology (7 papers). Jens Pahl is often cited by papers focused on Immune Cell Function and Interaction (17 papers), CAR-T cell therapy research (11 papers) and T-cell and B-cell Immunology (7 papers). Jens Pahl collaborates with scholars based in Germany, Netherlands and Canada. Jens Pahl's co-authors include Adelheid Cerwenka, Joachim Koch, Jing Ni, Matthias Miller, Arjan C. Lankester, Marco W. Schilham, Uwe Reusch, Martin Treder, Susy J. Santos and R. Maarten Egeler and has published in prestigious journals such as Blood, Clinical Cancer Research and Frontiers in Immunology.

In The Last Decade

Jens Pahl

19 papers receiving 780 citations

Peers

Jens Pahl

IMMUN

ONCOL

PRM

Virginia Cecconi Switzerland

Margaux Vienne France

Remy Thomas Qatar

James M. Leatherman United States

Sofia Mensurado Portugal

Karin M. Knudson United States

Chiara Massa Germany

Xuexiang Du United States

Aurélie Durgeau France

Anna‐Maria Georgoudaki Sweden

Virginia Cecconi Switzerland

Jens Pahl

680 ×1.2

IMMUN

357 ×0.9

ONCOL

310 ×1.7

67 ×0.7

86 ×1.2

PRM

Citations per year, relative to Jens Pahl Jens Pahl (= 1×) peers Virginia Cecconi

Countries citing papers authored by Jens Pahl

Since Specialization

Citations

This map shows the geographic impact of Jens Pahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Pahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Pahl more than expected).

Fields of papers citing papers by Jens Pahl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Pahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Pahl. The network helps show where Jens Pahl may publish in the future.

Co-authorship network of co-authors of Jens Pahl

This figure shows the co-authorship network connecting the top 25 collaborators of Jens Pahl. A scholar is included among the top collaborators of Jens Pahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Pahl. Jens Pahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guldevall, Karolin, Patrick A. Sandoz, Valentina Carannante, et al.. (2025). CD16A Shedding Regulates Innate Cell Engager‐Induced Serial Killing by Natural Killer Cells. European Journal of Immunology. 55(10). e70078–e70078.

Abba, Mohammed, Stefan Klein, Wolf‐Karsten Hofmann, et al.. (2024). The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient's NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS. Blood. 144(Supplement 1). 4143–4143. 1 indexed citations

Pinto, Sheena, Jens Pahl, Arndt Schottelius, Paul J. Carter, & Joachim Koch. (2022). Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. Trends in Immunology. 43(11). 932–946. 37 indexed citations

Pahl, Jens, Séverine Sarlang, Stefan Knackmuss, et al.. (2022). P482: NOVEL BISPECIFIC INNATE CELL ENGAGER AFM28 FOR THE TREATMENT OF CD123 POSITIVE ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME. HemaSphere. 6. 381–382. 1 indexed citations

Reusch, Uwe, Kristina Ellwanger, Ivica Fucek, et al.. (2021). Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30 + Malignancies. Blood. 138(Supplement 1). 3992–3992. 1 indexed citations

Pahl, Jens, Thomas Müller, Séverine Sarlang, et al.. (2021). AFM28, a Novel Bispecific Innate Cell Engager (ICE ®), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood. 138(Supplement 1). 3344–3344. 4 indexed citations

Wingert, Susanne, Uwe Reusch, Stefan Knackmuss, et al.. (2021). Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors. mAbs. 13(1). 1950264–1950264. 50 indexed citations

Pahl, Jens, et al.. (2020). Human innate immune cell crosstalk induces melanoma cell senescence. OncoImmunology. 9(1). 1808424–1808424. 7 indexed citations

Pahl, Jens, Joachim Koch, Annette Arnold, et al.. (2018). CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells. Cancer Immunology Research. 6(5). 517–527. 104 indexed citations

10.

Pahl, Jens, Adelheid Cerwenka, & Jing Ni. (2018). Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors. Frontiers in Immunology. 9. 2796–2796. 63 indexed citations

11.

Wingert, Susanne, Uwe Reusch, Jens Pahl, et al.. (2018). CD16A-Specific Tetravalent Bispecific Immune Cell Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) on Macrophages. Blood. 132(Supplement 1). 1111–1111. 2 indexed citations

12.

Breunig, Christian, Jens Pahl, Matthias Miller, et al.. (2017). MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. Cell Death and Disease. 8(8). e2973–e2973. 94 indexed citations

13.

Pahl, Jens, et al.. (2017). KIR downregulation by IL‐12/15/18 unleashes human NK cells from KIR/HLA‐I inhibition and enhances killing of tumor cells. European Journal of Immunology. 48(2). 355–365. 56 indexed citations

14.

Pahl, Jens, Uwe Reusch, Thorsten Gantke, et al.. (2016). AFM13 Is the Most Advanced Bispecific NK-Cell Engaging Antibody in Clinical Development Substantially Enhancing NK-Cell Effector Function and Proliferation. Blood. 128(22). 1764–1764. 2 indexed citations

15.

Pahl, Jens, Susy J. Santos, Marieke L. Kuijjer, et al.. (2015). Expression of the immune regulation antigen CD70 in osteosarcoma. Cancer Cell International. 15(1). 31–31. 22 indexed citations

16.

Pahl, Jens & Adelheid Cerwenka. (2015). Tricking the balance: NK cells in anti-cancer immunity. Immunobiology. 222(1). 11–20. 161 indexed citations

17.

Pahl, Jens, Kitty M.C. Kwappenberg, Eleni Maria Varypataki, et al.. (2014). Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ. Journal of Experimental & Clinical Cancer Research. 33(1). 27–27. 73 indexed citations

18.

Pahl, Jens, Kitty M.C. Kwappenberg, Monique M. van Ostaijen-ten Dam, et al.. (2013). Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity. Cancer Immunology Immunotherapy. 62(7). 1235–1247. 17 indexed citations

19.

Pahl, Jens, Kitty M.C. Kwappenberg, Jort Vellinga, et al.. (2012). Adenovirus type 35, but not type 5, stimulates NK cell activation via plasmacytoid dendritic cells and TLR9 signaling. Molecular Immunology. 51(1). 91–100. 16 indexed citations

20.

Pahl, Jens, Emilie P. Buddingh, Susy J. Santos, et al.. (2011). Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma. Clinical Cancer Research. 18(2). 432–441. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact